Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Utility of the Presence of Anti-SARS-CoV-2 Antibodies in Detecting COVID-19 in Symptomatic Children and Adolescents: An Analytical Cross-sectional Study

Author(s): Reza Sinaei, Kimia Iranmanesh*, Sara Pezeshki, Mohammad Hasannejad, Ali Hosseininasab, Saeedeh Parvaresh and Roya Sinaei

Volume 20, Issue 1, 2024

Published on: 06 November, 2023

Page: [38 - 46] Pages: 9

DOI: 10.2174/011573398X267876231017072820

Price: $65

Abstract

Background: Understanding immunoreactivity against SARS-CoV-2 provides a basis for the pathophysiology of COVID-19 while also providing a means to confirm the disease and reduce its transmission.

Methods: The present cross-sectional study was conducted from February 1st, 2020 to December 30th, 2022. The patients’ characteristics, clinical and laboratory data, Polymerase Chain Reaction (PCR) results, and the presence of anti-SARS-CoV-2 antibodies (serology testing) were recorded.

Results: A total of 182 children were included. PCR returned positive in 60.4%, while serology indicated infection in 86.4% of the participants. Sex as a factor was not significantly associated with the results of either of the tests. However, seropositive children were older (p < 0.001), while PCR-positive children were younger (p < 0.01). Those who presented with cough (p < 0.05) or Multisystem Inflammatory Syndrome (MIS-C) (p < 0.05) had higher seropositivity rates than those without. In contrast, those who presented with fever (p < 0.001) or seizures (p < 0.01) had higher chances of having a positive PCR for COVID-19. In individuals suffering from arthralgia, limping, or arthritis, positive serology was observed in 96.3%, 95.2%, and 96.9%, respectively. However, positive results from PCR were observed in 67.2%, 67.1%, and 30.3% of the mentioned individuals, respectively.

Conclusion: Anti-SARS-CoV-2 serology is a valuable diagnostic tool in individuals presenting late with arthralgia, arthritis, limping, MIS-C, or other delayed presentations, especially when PCR returns negative for the virus.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022. Available from:https://covid19.who.int/ (cited 2022 Dec 24)
[2]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[3]
Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: A narrative review. World J Pediatr 2021; 17(1): 10-20.
[http://dx.doi.org/10.1007/s12519-020-00392-y] [PMID: 32978651]
[4]
Badal S, Thapa Bajgain K, Badal S, Thapa R, Bajgain BB, Santana MJ. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis. J Clin Virol 2021; 135: 104715.
[http://dx.doi.org/10.1016/j.jcv.2020.104715] [PMID: 33348220]
[5]
Karimi Afshar N, Sinaei R, Hoseininasab A, et al. Post and during SARS-Cov-2 syndrome in children. Curr Respir Med Rev 2023; 19(3): 234-8.
[http://dx.doi.org/10.2174/1573398X19666230720114556]
[6]
Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med 2020; 12(564): eabd5487.
[http://dx.doi.org/10.1126/scitranslmed.abd5487] [PMID: 32958614]
[7]
Gruber CN, Patel RS, Trachtman R, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-c). Cell 2020; 183(4): 982-995.e14.
[http://dx.doi.org/10.1016/j.cell.2020.09.034] [PMID: 32991843]
[8]
Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol 2021; 22(1): 25-31.
[http://dx.doi.org/10.1038/s41590-020-00826-9] [PMID: 33154590]
[9]
Dowell AC, Butler MS, Jinks E, et al. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol 2022; 23(1): 40-9.
[http://dx.doi.org/10.1038/s41590-021-01089-8] [PMID: 34937928]
[10]
Bartsch YC, Wang C, Zohar T, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med 2021; 27(3): 454-62.
[http://dx.doi.org/10.1038/s41591-021-01263-3] [PMID: 33589825]
[11]
Anderson EM, Diorio C, Goodwin EC, et al. Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) antibody responses in children with multisystem inflammatory syndrome in children (MIS-c) and mild and severe coronavirus disease 2019 (COVID-19). J Pediatric Infect Dis Soc 2021; 10(5): 669-73.
[http://dx.doi.org/10.1093/jpids/piaa161] [PMID: 33263756]
[12]
Rostad CA, Chahroudi A, Mantus G, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-c). Pediatrics 2020; 146(6): e2020018242.
[http://dx.doi.org/10.1542/peds.2020-018242] [PMID: 32879033]
[13]
Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest 2020; 130(11): 5967-75.
[http://dx.doi.org/10.1172/JCI140970] [PMID: 32730233]
[14]
Consiglio CR, Cotugno N, Sardh F, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 2020; 183(4): 968-981.e7.
[http://dx.doi.org/10.1016/j.cell.2020.09.016] [PMID: 32966765]
[15]
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169.
[http://dx.doi.org/10.3389/fmicb.2021.698169] [PMID: 34248921]
[16]
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21(3): 133-46.
[http://dx.doi.org/10.1038/s41579-022-00846-2] [PMID: 36639608]
[17]
Slouma M, Abbes M, Mehmli T, et al. Reactive arthritis occurring after COVID-19 infection: A narrative review. Infection 2023; 51(1): 37-45.
[http://dx.doi.org/10.1007/s15010-022-01858-z] [PMID: 35655110]
[18]
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63(3): 364-74.
[http://dx.doi.org/10.1007/s11427-020-1643-8] [PMID: 32048163]
[19]
Guo J, Ge J, Guo Y. Recent advances in methods for the diagnosis of corona virus disease 2019. J Clin Lab Anal 2022; 36(1): e24178.
[http://dx.doi.org/10.1002/jcla.24178] [PMID: 34921443]
[20]
Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography 2021; 27(2): 682-7.
[http://dx.doi.org/10.1016/j.radi.2020.09.010] [PMID: 33008761]
[21]
Law S, Tovar MA, Franke MF, et al. Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru. BMC Infect Dis 2023; 23(1): 62.
[http://dx.doi.org/10.1186/s12879-023-08003-7] [PMID: 36732690]
[22]
Jubair M, Rahman S, Begum MN, et al. SARS-CoV-2 antigen detection by saliva; an alternative to nasopharyngeal specimen: A cross-sectional study. Health Sci Rep 2023; 6(5): e1275.
[http://dx.doi.org/10.1002/hsr2.1275] [PMID: 37216057]
[23]
Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020; 323(22): 2249-51.
[http://dx.doi.org/10.1001/jama.2020.8259] [PMID: 32374370]
[24]
Qin X, Gao P, Zhang Z, et al. A low-cost and high-efficiency 10-in-1 test for the PCR-based screening of SARS-CoV-2 infection in low-risk areas. Chin Med J 2022; 135(4): 496-8.
[http://dx.doi.org/10.1097/CM9.0000000000001627] [PMID: 34267070]
[25]
Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol 2020; 9(5): e1136.
[http://dx.doi.org/10.1002/cti2.1136] [PMID: 32382418]
[26]
Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020; 6(5): 591-605.
[http://dx.doi.org/10.1021/acscentsci.0c00501] [PMID: 32382657]
[27]
Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020; 52(5): 731-3.
[http://dx.doi.org/10.1016/j.immuni.2020.04.003] [PMID: 32325025]
[28]
Burgess S, Ponsford MJ, Gill D. Are we underestimating seroprevalence of SARS-CoV-2? BMJ 2020; 370: m3364.
[http://dx.doi.org/10.1136/bmj.m3364] [PMID: 32883673]
[29]
Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol 2020; 5(47): eabc6347.
[http://dx.doi.org/10.1126/sciimmunol.abc6347] [PMID: 32430309]
[30]
Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 2020; 6(6): CD013652.
[PMID: 32584464]
[31]
Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis. BMJ 2020; 370: m2516.
[http://dx.doi.org/10.1136/bmj.m2516] [PMID: 32611558]
[32]
Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Res 2014; 194: 175-83.
[http://dx.doi.org/10.1016/j.virusres.2014.03.018] [PMID: 24670324]
[33]
Huang LR, Chiu CM, Yeh SH, et al. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J Med Virol 2004; 73(3): 338-46.
[http://dx.doi.org/10.1002/jmv.20096] [PMID: 15170626]
[34]
Jin Y, Wang M, Zuo Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis 2020; 94: 49-52.
[http://dx.doi.org/10.1016/j.ijid.2020.03.065] [PMID: 32251798]
[35]
Xie J, Ding C, Li J, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol 2020; 92(10): 2004-10.
[http://dx.doi.org/10.1002/jmv.25930] [PMID: 32330303]
[36]
Ricke DO. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front Immunol 2021; 12: 640093.
[http://dx.doi.org/10.3389/fimmu.2021.640093] [PMID: 33717193]
[37]
Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody responses in COVID-19: A review. Front Immunol 2021; 12: 633184.
[http://dx.doi.org/10.3389/fimmu.2021.633184] [PMID: 33936045]
[38]
Chang FY, Chen HC, Chen PJ, et al. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). J Biomed Sci 2020; 27(1): 72.
[http://dx.doi.org/10.1186/s12929-020-00663-w] [PMID: 32498686]
[39]
COVID-19 One-Step RT-PCR – Pishtazteb Diagnostics. 2021. Available from:http://pishtazteb.com/en/products/molecular-kits/covid-19-one-step-rt-pcr/
[40]
COVID-19 One-Step Elisa kits – Pishtazteb Diagnostics. 2021. Available from:https://pishtazteb.com/en/products/elisa-kits/cov-detection/cov-2-s-ag-elisa/
[41]
Naeimi R, Sepidarkish M, Mollalo A, et al. SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. EClinicalMedicine 2023; 56: 101786.
[http://dx.doi.org/10.1016/j.eclinm.2022.101786] [PMID: 36590788]
[42]
Rostami A, Sepidarkish M, Fazlzadeh A, et al. Update on SARS-CoV-2 seroprevalence: Regional and worldwide. Clin Microbiol Infect 2021; 27(12): 1762-71.
[http://dx.doi.org/10.1016/j.cmi.2021.09.019] [PMID: 34582980]
[43]
Josephson A, Kilic T, Michler JD. Socioeconomic impacts of COVID-19 in low-income countries. Nat Hum Behav 2021; 5(5): 557-65.
[http://dx.doi.org/10.1038/s41562-021-01096-7] [PMID: 33785897]
[44]
Zar HJ, Dawa J, Fischer GB, Castro-Rodriguez JA. Challenges of COVID-19 in children in low- and middle-income countries. Paediatr Respir Rev 2020; 35: 70-4.
[PMID: 32654854]
[45]
Stringhini S, Zaballa ME, Perez-Saez J, et al. Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis 2021; 21(5): 600-1.
[http://dx.doi.org/10.1016/S1473-3099(21)00054-2] [PMID: 33539733]
[46]
Franczak J, Moppert J, Sobolewska-Pilarczyk M, Pawłowska M. The seroprevalence of SARS-CoV-2 IgG antibodies in children hospitalized for reasons other than COVID-19. J Clin Med 2022; 11(13): 3819.
[http://dx.doi.org/10.3390/jcm11133819] [PMID: 35807103]
[47]
Wang R, Jin F, Cao S, et al. Seroprevalence of SARS-CoV-2 infections among children visiting a hospital. Pediatr Investig 2020; 4(4): 236-41.
[http://dx.doi.org/10.1002/ped4.12231] [PMID: 33376950]
[48]
Sinaei R, Pezeshki S, Parvaresh S, et al. Post SARS-CoV-2 infection reactive arthritis: A brief report of two pediatric cases. Pediatr Rheumatol Online J 2021; 19(1): 89.
[http://dx.doi.org/10.1186/s12969-021-00555-9] [PMID: 34118941]
[49]
Crivelenti LRMP, Frazão MMN, Maia MPM, Gomes FHR, de Carvalho LM. Chronic arthritis related to SARS-CoV-2 infection in a pediatric patient: A case report. Braz J Infect Dis 2021; 25(3): 101585.
[http://dx.doi.org/10.1016/j.bjid.2021.101585] [PMID: 34043944]
[50]
Werner SG, Langer H-E. The first case of reactive arthritis associated with SARS-CoV-2-infection in A 4-year old child. Res Square 2020; 2020

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy